The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Tislelizumab for R/R classical Hodgkin lymphoma
Yuqin Song, PhD, of Peking University Cancer Hospital & Institute, Beijing, China, presents the preliminary results of a Phase II trial investigating the immune checkpoint inhibitor tislelizumab (BGB-A317) for the treatment of relapsed/refractory classical Hodgkin lymphoma patients that have failed or were ineligible for autologous stem cell transplant (NCT03209973). Dr Song reports a best overall response rate of 86% and minimal side effects consisting of predominantly pyrexia, hypothyroidism and weight increase. Dr Song was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
